Midatech Pharma PLC Notice of Interim Results (9160Z)
September 06 2018 - 1:01AM
UK Regulatory
TIDMMTPH
RNS Number : 9160Z
Midatech Pharma PLC
06 September 2018
6 September 2018
Midatech Pharma PLC
("Midatech" or the "Company")
Notice of Interim Results
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international
specialty pharmaceutical company focused on developing and
commercialising products for rare diseases in oncology and
immunotherapy, announces that it will release its interim results
for the six months ending 30 June 2018 on Thursday 27 September
2018.
Dr Craig Cook, Chief Executive Officer, and Nick Robbins-Cherry,
Chief Financial Officer, will host a presentation and conference
call at 14.00 BST at the offices of Panmure Gordon & Co, One
New Change, London, EC4M 9AF. Details of the conference call will
be published on the day of results. A recording of the call will be
available shortly afterwards at
www.midatechpharma.com/presentations-reports.
- Ends -
For more information, please contact:
Midatech Pharma PLC
Craig Cook, CEO
+44 (0)1235 888300
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate finance: Freddy Crossley / Emma Earl
Corporate broking: James Stearns
+44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR)
Mary-Jane Elliott / Nicholas Brown / Angela Gray
+44 (0)20 3709 5700
midatech@consilium-comms.com
Westwicke Partners (US Investor Relations)
Chris Brinzey
+1 339 970 2843
chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company
focused on developing and commercialising products in oncology and
immunotherapy for rare diseases via both in-house and partnered
programs. Our development pipeline of improved chemo- and
immune-therapeutic drug candidates utilises Midatech's three
platform drug delivery technologies, Midacore(TM), Q-Sphera(TM) and
Nano-Inclusion technologies:
- Midacore(TM) is a leading gold nanoparticle technology that we
are exploiting for targeted delivery of: i) existing
chemotherapeutic agents to cancer cells, and ii) antigenic peptides
to the immune system for immune-oncology applications.
- Q-Sphera(TM) platform: our piezo-electric polymer microsphere
technology for sustained release at the microscale to prolong and
control the release of therapeutics over an extended period of time
from weeks to months.
- Nano-Inclusion platform: a nanosaccharide technology, used to
dissolve drugs at the nanoscale for direct brain delivery of
aqueous formulations to treat brain tumours
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORLLFIDATIEIIT
(END) Dow Jones Newswires
September 06, 2018 02:01 ET (06:01 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024